Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

PHASE2TerminatedINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

October 24, 2016

Primary Completion Date

July 27, 2018

Study Completion Date

July 27, 2018

Conditions
Non-Alcoholic Steatohepatitis
Interventions
DRUG

SHP626

5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion

DRUG

Placebo

Matching placebo

Trial Locations (65)

10016

Concorde Medical Group PLLC, New York

11030

Northwell Health Inc., Manhasset

14642

University of Rochester Medical Center, Rochester

15213

University of Pittsburgh Medical Center, Pittsburgh

20007

Medstar Georgetown University Hospital, Washington D.C.

20037

George Washington (GW) Medical Faculty Associates, Washington D.C.

21202

Mercy Medical Center, Baltimore

21228

Digestive Disease Associates, Catonsville

23226

Bon Secours Liver Institute of Virginia, Richmond

23249

McGuire VA Medical Center, Richmond

23502

Digestive and Liver Disease Specialists, Norfolk

27710

DUMC-Gastroenterology, Durham

28204

Center for Liver Disease, Charlotte

28304

Cumberland Research Associates, LLC, Fayetteville

28677

Carolinas Center for Liver Disease, Statesville

29425

Medical University of South Carolina, Charleston

30060

Gastrointestinal Specialists of Georgia, Marietta

30312

Internal Medicine Associates of Wellstar Atlanta Medical, Atlanta

30322

Emory University, Atlanta

33136

Schiff Center for Liver Diseases, Miami

33414

South Florida Center of Gastroenterology, Wellington

37211

Quality Medical Research, Nashville

37421

Clinsearch, LLC, Chattanooga

39216

University of Mississippi Medical Center, Jackson

40202

Liver Research Center, Louisville

48377

Henry Ford Health System, Novi

52242

University of Iowa Hospitals and Clinics, Iowa City

53792

UW Digestive Health Center (DHC), Madison

64157

Kansas City Research Institute, Kansas City

70112

Tulane University Health Sciences Center, New Orleans

71105

Louisiana Research Center, LLC, Shreveport

75082

DHAT Research Institute, Richardson

75203

Methodist Health Systems Clinical, Dallas

77030

Baylor College of Medicine - Advanced Liver Therapies, Houston

Texas Children's Hospital, Houston

78756

Austin Center for Clinical Research, Austin

80113

South Denver Gastroenterology, PC, Englewood

90048

Ceders-Sinai Medical Center, Los Angeles

91105

California Liver Research Institute, Pasadena

92118

Southern California Research Center, Coronado

92377

Inland Empire Liver Foundation, Rialto

93720

Fresno Clinical Research Center, Fresno

96813

The Queen's Medical Center - Liver Center, Honolulu

98101

Virginia Mason Medical Center, Seattle

02215

Beth Israel Deaconess Medical Center, Boston

01605

University of Massachusetts Medical School, Worcester

03756

Dartmouth Hitchcock Medical Center, Lebanon

038104

University of TN Health Science Center, Memphis

05401

UVM Medical Center, Burlington

T2N 4Z5

University of Calgary Liver Unit, Calgary

V5Z 1H2

LAIR Centre, Vancouver

V6Z 2C7

Vancouver ID Research and Care Centre Society, Vancouver

B3HJ 2Y9

Nova Scotia Heath Authority, Halifax

M6H 3M1

Toronto Liver Centre, Toronto

H2X 0A9

CRCHUM, Montreal

00935

UPR: Medical Sciences Campus, San Juan

NW3 2QG

Royal Free Hospital, Hampstead

NR4 7UY

Norfolk & Norwich University Hospital, Norwich

OX3 9DU

John Radcliffe Hospital, Oxford

DD1 9SY

NHS Tayside, Dundee

B15 2TH

University Hospital Birmingham, Birmingham

E1 1BB

Royal London Hospital, London

NG7 2UH

Nottingham Digestive Diseases Centre and Biomedical Research Unit, Nottingham

SA2 8QA

Abertawe Bro Morgannwg University, Swansea

YO31 8HE

York Clinical Research Facility, York

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY